InflaMix Identifies CAR-T Recipients with a Preinfusion Inflammatory Profile Indicative of High Risk for CAR-T Treatment Failure By Ogkologos - May 5, 2025 331 0 Facebook Twitter Google+ Pinterest WhatsApp A valuable tool for point-of-care clinical decision-making in patients with non-Hodgkin lymphoma Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR News digest – smoking ban, HPV and prostate cancer, genetic testing... July 18, 2020 Breastfeeding Duration Could Influence Breast Cancer Risk, Study Shows September 27, 2019 Young Breast Cancer Survivor Killed in Hit and Run Crash Weeks... August 25, 2021 Woman Suffers Severe Eye Pain And Swelling, Finds Out She Has... April 17, 2019 Load more HOT NEWS ΚΑΡΚΙΝΟΣ ΤΟΥ ΜΑΣΤΟΥ Girls Aloud members to join forces to raise money in Sarah... FDA Approves Pembrolizumab with Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube,... What to Know About Navigating Cancer Care With a Disability: An...
